The aim of this study was to develop roflumilast dry powder inhaler (DPI) formulations by spray drying using hydroxypropyl-β-cyclodextrin (HPβCD) and to determine their suitability for pulmonary delivery. Different feed solution concentrations, solvent systems and spray drying parameters were used to obtain the formulations which were characterized using X-ray powder diffraction, thermal analysis, scanning electron microscopy, particle size distribution, bulk and tapped density, specific surface area, dynamic vapour sorption, in vitro deposition properties using a Next Generation Impactor (NGI) and transepithelial permeability. Microparticles spray dried from ethanol were wrinkled and amorphous, exhibiting high glass transition temperatures while those from methanol:n-butyl acetate consisted of irregularly shaped porous particles partially crystalline. All formulations presented low density, particle size and residual solvent content exhibiting high depositon in the lower stages of the NGI. Mass median aerodynamic diameters (MMADs) were in the range of 3.32-4.49 μm, with high fine particle fractions (FPF < 5 μm). Stability studies demonstrated no significant modifications in the solid-state nature and in the aerolisation performance of the selected formulation which presented a P app of 8.73 × 10 −6 ± 4.70 × 10 −7 cm/s. The developed roflumilast DPI formulations have potential therapeutic applications in the treatment of lung diseases.
Introduction
According to the Global Initiative for Asthma, around 300 million people worldwide suffer from asthma, representing the respiratory disease of highest prevalence, followed by chronic obstructive pulmonary disease (COPD) which is responsible for approximately 3 million deaths annually. The prevalence of COPD is expected to rise over the next 30 years, with the possibility of 4.5 million deaths annually by 2030 (GINA, 2018; Gold, 2017) . Asthma and COPD have relevant and increasing epidemiological and economic impact worldwide, with associated health costs increasing with the worsening of the pathologies (Roggeri et al., 2016) .
Roflumilast (3-cyclo-propylmethoxy-4-difluoromethoxy-N-[3,5-dichloropyrid-4-yl] -benzamide) is a once-daily phosphodiesterase type 4 (PDE4) inhibitor, which is used to provide long-term maintenance therapy for COPD and asthma (Pinheiro et al., 2018) . It was the first drug approved by the FDA for the treatment of COPD and is commercially available as Daliresp® oral tablets containing 500 µg of roflumilast (Pinheiro et al., 2017; Sun et al., 2015) . However, it has been reported that the full clinical impact of orally active PDE4 inhibitors has been limited by their mechanism-based gastrointestinal side effects and unexplained weight loss (Tashkin, 2014) .
With a view to improving the therapeutic index of PDE4 inhibitors and to minimizing their side effects, pulmonary delivery represents a potential alternative to oral drug delivery, with the opportunity to prevent gastric side effects and additional potential for increased bioavailability, as first-pass metabolism in the liver is avoided (Chen et al., 2016) . Additionally, pulmonary drug delivery would be local, as receptors for these inhibitors are present at several locations of the lungs (Grundy et al., 2016) , providing for a rapid onset of action with possibly lower doses.
The protective effects of inhaled roflumilast on lung function was studied by Chapman et al. (2007) , who demonstrated inhaled roflumilast to be more effective than the orally delivered drug. In their studies, the authors delivered micronized drug admixed with lactose by intratracheal administration using a fine-tipped dry powder microspray needle and by nose-only inhalation in Brown Norway rats. The results support the hypothesis that inhaled PDE4 inhibitors will be efficacious in inflammatory lung diseases, particularly for the improvement of lung function. However, to date there is no commercially available pulmonary formulation of this active pharmaceutical ingredient (API).
There are typically three platforms of devices used to aerosolise drugs for inhalation: nebulizer, pressurized metered-dose inhaler (pMDI) and dry powder inhaler (DPI). DPIs have attracted substantial interest for the development of pulmonary drug delivery systems for systemic and local therapies in comparison to the others, being breathactivated, propellant-free and involving a solid state formulation (Xu et al., 2014) . For efficient deposition within the central and alveolar regions of the lung, the most favorable aerodynamic diameter of particles for inhalation is between approximately 1 and 5 μm. Spray drying is an attractive and scalable solidification technique; it has been used as a common approach for powder preparation for a wide range of drugs, including commercial products, and is especially suited to preparing powders for inhalation. This process allows various parameters to be controlled in order to optimize particulate product characteristics, such as particle size, particle size distribution and particle shape. Furthermore, spray drying enables the incorporation of excipients to improve the dispersibility of the powder, to optimise the stability of the API, to enhance the absorption of the API across the pulmonary epithelium following delivery, or to generate powders that display a modified drug release profile (Tewes et al., 2014; Xu et al., 2014) .
The amorphous state of solid dipersions that often results from spray drying can compromise formulation stability. Excipients such as the oligosaccharide, hydroxypropyl-β-cyclodextrin (HPβCD), have been demonstrated to enhance API stability by increasing the glass transition temperature (T g ) of the amorphous solid dispersion and preventing/ delaying recrystallization of same. HPβCD is present in a range of commercially available injectable formulations (Chelly et al., 2018) , and has been shown to be safe in application to the human airway epithelial Calu-3 cells in vitro, presenting the potential to be used in commercial dry powders for inhalation formulations (Amaro et al., 2015a; Vartiainen et al., 2016) . HPβCD is also well known to present the ability to form water soluble complexes with poorly water soluble drugs, and can increase drug molecule permeability and bioavailability (Dufour et al., 2015; Healy et al., 2014) .
The aim of the present study was to develop a novel roflumilast DPI formulation using HPβCD as an excipient/carrier, to optimize the manufacture of a DPI formulation by spray drying, and to characterize the formulated product with respect to its suitability for pulmonary drug delivery. In addition, formulation stability under controlled temperature and humidity conditions and in vitro drug absorption in a pulmonary cell line were also assessed.
Materials and methods

Materials
Roflumilast was purchased from Biochempartner (Shanghai, China), hydroxypropyl-β-cyclodextrin (HPβCD) was purchased from Thermo Fisher Scientific (Dublin, Ireland). Solvents used were: n-butyl acetate (BA) purchased from Merck (Nottingham, UK), methanol (MeOH) and acetonitrile purchased from Sigma-Aldrich (Dublin, Ireland), and ethanol obtained from Lab Scan Analytical Sciences (Dublin, Ireland). Deionised water was obtained from a Purite Prestige Analyst HP (Millipore, Carrigtwohill, Ireland) water purification system.
Spray drying
All solutions prepared were spray dried with a Bϋchi B-290 Mini spray dryer (Bϋchi, Flawil, Switzerland) in the closed mode, using a standard 2-fluid nozzle with a 0.7 mm tip and 1.5 mm cap and the high performance efficiency cyclone. The pump setting and the aspirator capacity were set at 30% and 100%, respectively. The composition of the various formulations and spray drying parameters are presented in Table 1 . Yields are calculated based on the ratio between the weight percentage of the final product to the quantity of the materal input to the feed solution. ET5N and ET5R formulations were prepared in duplicate.
Formulation ET5R contains an amount of API estimated to be required for a therapeutic effective dose to be inhaled. The dose was calculated based on dose ratios for other APIs that are commercially available for both inhalation and oral administration, such as albuterol, terbutaline and metaproterenol, in which cases the inhaled dose is approximately 10 times lower than the oral dose.
X-ray powder diffraction (XRPD)
A Rigaku Miniflex II desktop X-ray diffractometer (Tokyo, Japan) with Haskris (Elk Grove Village, Illinois, USA) WA1 cooling unit was used to determine the X-ray powder diffraction patterns from 3°to 40°o n the two theta (θ) scale at a step size of 0.05°per s. Samples were run in triplicate.
Differential scanning calorimetry (DSC)
DSC measurements were carried out in triplicate using a DSC Q200 TA instrument (TA instruments, Elstree, United Kingdom) with sample weights of 2.5-3.5 mg loaded into 40 µL aluminium pans with three vent holes. Samples were scanned over a temperature range of 0-250°C at a rate of 5°C/min, ± 0.796 modulation amplitude and 60 s modulation period. The glass transition temperature of roflumilast raw material was determined by the melt quench technique, through heating the sample to 170°C, and subsequently fast cooling; the sample was then scanned over a temperature range of 0-170°C with a scanning rate of 2°C/min and 1.0 modulation and a period of 60 s. Universal Analysis® (version 4.7A) software was used to analyze the data.
Thermogravimetric analysis (TGA)
Thermogravimetric analysis was carried out using a Mettler TG50 (Metter Toledo Ltd, Greifensee, Switzerland) linked to a Mettler MT5 balance. Mettler Toledo STARe software was used to process the data. Sample weights of approximately 5 mg were analysed using open pans under nitrogen purge. All analyses were performed in triplicate at a heating rate of 10°C/min from 25 to 200°C.
Scanning electron microscopy (SEM)
A Zeiss Ultra Plus (Oberkochen, Germany) was used to take the scanning electron micrographs of all samples. Samples were fixed on aluminum stubs using double-sided carbon tape and sputter-coated with gold. Micrographs were collected at different magnifications.
Particle size distribution (PSD)
Particle size distributions of powder samples were measured using a Malvern Mastersizer 2000 (Malvern Instruments Ltd., Worcestershire, UK) laser difraction instrument coupled with a Scirocco 2000 dry powder dispersion accessory. A vibration feed rate of 50% and dipersive air pressure of 2.0 bar were set to run the samples. Table 1 Composition, inlet, outlet temperature, air flow, yield, particle size, specific surface area, bulk and tapped density, glass transition, residual solvent content and drug loading of the spray dried formulations. (1)
Measurements for each sample were carried out in triplicate.
Bulk and tapped density
Bulk and tapped density were determined using a 1 mL graduated glass syringe as previously described (Amaro et al., 2015a; Healy et al., 2008; Nolan et al., 2009 ). The results presented are the average of three determinations.
Specific surface area (SSA)
Specific surface area of spray dried powders was measured by gas adsorption using a Micromeritics Gemini VI surface area analyser (Micromeritics, Hertfordshire, UK). Samples were previously degassed for 12 h at 25°C using a Micromeritics FlowPrep 060 Degasser (Micromeritics, Hertfordshire, UK). For all samples the volume of nitrogen adsorbed was measured at the relative pressures of 0.05, 0.1, 0.15, 0.2, 0.25 and 0.3. Adsorption data for relative pressures 0.05 < P/P 0 < 0.3 was used to calculate the SSA by the BET equation (Amaro et al., 2011; Gregg and Sing, 1982) . Analyses were carried out in triplicate.
Dynamic vapour sorption (DVS)
The water vapour sorption-desorption isotherms of the samples were determined using an automated gravimetric vapour sorption analyzer, DVS Advantage-1 (Surface Measurements Systems Ltd., London, UK). Samples were equilibrated under nitrogen purge to remove any residual solvents and to establish a dry reference mass. They were then exposed to 0-90% RH in increments of 10% RH and the reverse for desorption, at a constant temperature of 25 ± 0.1°C. Before changing the RH at each stage, the sample mass reached the equilibrium (dm/dt = 0.002 mg/min over 10 min). The amount of water uptake for each stage was expressed as a % of the dry sample mass (m 0 ) (Amaro et al., 2015a,b; Tewes et al., 2010) .
High performance liquid chromatography (HPLC)
A HPLC method adapted from Assi et al. (2006) was used in order to quantify roflumilast. A Breeze™ HPLC system (Waters, Milford, USA) equipped with Waters 1525 binary pump with an in-built degasser, Waters 717 plus autosampler and Waters 2487 dual λ absorbance detector was used. Chromatographic separation was performed isocratically at room temperature using a 250 mm × 4.0 mm i.d. (5 µm particle size) Kromasil C 18 column (Tedia, Brazil). The mobile phase consisted of acetonitrile and 5 mM sodium dihydrogen orthophosphate, pH 3 (60:40%, v/v) and was run at flow rate of 1.0 mL min −1 with detection at 214 nm. Each measurement was performed in triplicate. The retention time for roflumilast was 4.6 min.
2.12. In vitro aerosol deposition studies using the next generation impactor (NGI)
The aerodynamic particle size distribution was measured according to the pharmacopoeial conditions (USP, 2014) using a Next Generation Impactor (NGI, Copley Scientific Limited, Nottingham, UK). The flow rate was adjusted to 60 L/min with the powder inhaler (Handihaler®, Boeringher Ingelheim, Germany) attached, and the time of aspiration was adjusted to obtain 4 L. In this condition, critical sonic flow was assured (P3/P2 < 0.5) and the flow rate was assumed to be stable. NGI stages were coated with 1 mL of ethanol. Spray dried powders were weighed (20 ± 2 mg) and loaded into no. 3 hard gelatin capsules. One capsule was used per test for each formulation (and testing was carried out at least in triplicate), except for ET5R, for which, due its low drug loading and HPLC limit of quantification, 10 capsules were used per test. Samples were collected in an appropriate volume of ethanol and quantified by HPLC. Each test was carried out at least in triplicate. The total mass of particles with aerodynamic diameters smaller than 5 µm was calculated by interpolation from the inverse of the standard normal cumulative mass distribution less than the stated size cut-off against the natural logarithm of the cut-off diameter of the respective stages. This amount was considered to be the fine particle fraction (FPF) and expressed as a percentage of the emitted recovered dose (ED). The mass median aerodynamic diameter (MMAD) of particles was determined from the same plot as the particle size at which the line crosses the 50% mark (Amaro et al., 2011 (Amaro et al., , 2015b .
Roflumilast-load quantification
Roflumilast load in the spray dried particles was determined by the HPLC method reported in Section 2.11. Each formulation was measured in triplicate. The loading efficiency was defined as the ratio of the experimentally determined loading to the theoretical loading which was calculated based on the ratio of roflumilast mass to the mass of total solid.
Stability studies
Stability studies were performed on the bulk powder of the ET5N formulation using the temperature and humidity conditions indicated for long term stability as per ICH1Q (R2) (Nyqvist, 1983) to maintain a constant relative humidity of 60%. Another stability condition of 25°C/ < 10%RH (dessicator) was also assessed. The ET5N bulk powder was stored in the same manner, using silica gel to provide dry conditions instead of a saturated salt solution. All sample storage conditions were monitored using the Amebis Stability Testing and Monitoring System (Amebis Ltd., Ireland). For the long term condition of 25°C/60%RH capsules were filled immediately prior to NGI testing; for the 25°C/ < 10%RH (dessicator) condition capsule filling was performed 24 h in advance, and capsules were kept under dessicant conditions in order to prevent undesirable moisture sorption by the bulk powder or gelatin capsule. After 4 and 8 weeks, bulk powder was tested by XRPD, SEM and NGI analysis. At 4 weeks the following analysis was also undertaken: particle size, specific surface area, bulk and tapped density, DSC and TGA.
Transepithelial permeability
Calu-3 cells were obtained from Banco de Células do Rio de Janeiro and maintained in Dulbecco's minimum essential medium (DMEM) (Sigma; Saint Louis, USA), with 10% fetal bovine serum and supplemented with penicillin G and streptomycin sulfate.
Cell monolayers were grown in a liquid covered culture (LCC) configuration on Transwell® polyester filters (pore size 0.4 μm, surface area 1.12 cm 2 , Corning Costar, Midland, USA) at an initial density of 5 × 10 5 cells/ well at 37°C, 5% CO 2 . The transepithelial electrical resistance (TEER) of cell layers was measured with a Millicell® ERS-2 Voltohmmeter and a stick electrode (2 measurements/filter) in culture medium (during the culture of cell layers) or Hank's Balanced Salt Solution (HBSS) before and after the permeation studies. The experiment was conducted when the cultured monolayers had a constant TEER value (600-700 Ω cm 2 ). A ET5N concentration of 250 µM was used and aplied to the apical side. The basal sample was collected every 60 min by moving the Transwell to a fresh well containing HBSS. All studies were perfomed four times over a 240 min period. All collected samples were analyzed using the HPLC method detailed above and the apparent permeability coefficient P app (cm·s 
where (dQ/dt) is the flux of drug, A is the surface area of the Transwell, and C 0 the initial concentration in the apical compartment (Mathias et al., 2002) .
Statistical analysis
Statistical analysis was undertaken using either Student's t-test or ANOVA followed by the posthoc Tukey's test, when there were three or more sets of data. GraphPad Prism® software (version 5.0) was used for statistical analysis. Parameters were considered significant at at least the 95% confidence level.
Results and discussion
Production of roflumilast DPI formulations using HPβCD by spray drying
In the present work, formulations containing roflumilast were prepared in a cyclodextrin carrier matrix by spray drying using different solvent systems and processing conditions: MB3, ET3, ET4, ET5, ET5N, ET5R (Table 1) . Yields ranged between 71.5% and 81.3%. The drug loading was from 90.2 up to 96.0% for 9:1 ratio formulations and 93.4% for the 1:400 ratio formulation (ET5R). The yields and drug loading were considered adequate. Yield loss was due to powder adhesion to the cyclone and drying chamber walls, the fine particle size obtained with loss of powder to the filter, and incapacity of entrapment by the cyclone. These common routes of yield loss have been previously described (Maury et al., 2005; Amaro et al., 2015b; Sosnik and Seremeta, 2015) . Additionally, the process was not optimised in the current study for yield improvement.
Drug loading loss can occur due to API adhesion to the materials of construction of the spray dryer or solution vessel, chemical degradation derived from the spray drying conditions used such as pressure experienced in the spray nozzle and inlet and outlet temperature. The addition of excipient is intended to promote chemical and physical stability of the API (Amaro et al., 2015b) .
Physicochemical characterization
Scanning electron micrographs showed that ethanol spray dried formulations (ET) presented, in general, wrinkled or raisin-like microparticles (Fig. 1) . Wrinkled particles have previously been assessed for (2016) studied microparticles prepared from ethanol/water solutions containing rivastigmine hydrogen tartrate and inulin with and without L-leucine (Leu). The higher proportion of this amino acid in the formulation, the more wrinkled was the surface and the smaller the particle size. The low solubility of Leu favors its precipitation/crystallization on the surface of drying droplets. The raisin morphology by means of the use of Leu has been also described by Healy et al. (2014) . The use of ethanol as solvent seems to be essential to produce wrinkled particles on spray drying roflumilast together with HPβCD. Previous studies demonstrated that HPβCD is associated with a high Peclet number (Anton et al., 2012 , Dufour et al., 2015 , which means that, on spray drying, the evaporation rate at the droplet surface is faster than the rate at which the dissolved components diffuse towards the centre, forming a shell around the droplet. The solvent inside the droplet continues to evaporate leading the shell to crumple and form the wrinkled microparticles (Vehring, 2008) . The wrinkled morphology can be associated with an improvement in aerosolisation performance due the lower true area of particle-particle contact resulting from surface asperities. In addition, surface roughness can greatly reduce the adhesion between solids, due to the high surface asperities, resulting in a prising apart of surfaces and breaking of interparticulate contacts (Amaro et al., 2011; Tabor, 1977) .
The MB3 formulation, which was spray dried from methanol:butyl acetate, consisted of porous, irregular shaped particles similar to those previously reported by Amaro et al. (2015a) and Paluch et al. (2012) , with some isolated fiber-like particles visible (pointed out in Fig. 1 ). This type of porous particle morphology was previously found to improve the aerolisation properties of powders, due to reduced interparticulate attractive forces and improved flow characteristics (Healy et al., 2008 Nolan et al., 2009 ). Other authors also obtained good results using the same solvent system (Amaro et al., 2015b; Ní Ógáin et al., 2011) . The particle formation is dependent on the solvent ratio and the material solubility characteristics that, together with the process parameters, will control the production of more or less porous particles (Amaro et al., 2015b; Nolan et al., 2011). With respect to the particle morphology, both MB3 and ET formulations have potential for improved efficiency of administration to the lungs in the dry form using a DPI. However, ethanol is a safer solvent than methanol:butyl acetate, and formulations spray dried from ethanol had a lower residual solvent content (RSC) than MB3 (Table 1) . The International Conference on Harmonization (ICH) guidelines (2016) classifies methanol as class 2 and butyl acetate and ethanol as class 3 residual solvents. Solvents in class 3, such as ethanol, are considered less toxic and of lower risk to human health. The RSC determined by TGA ranged from 5.06 to 7.28%, with the highest value being found for MB3 (Table 1) .
DSC and XRPD results showed that the MB3 formulation was not completely amorphous, in contrast to formulations spray dried from ethanol. There were two characteristic peaks in the XRPD of MB3, at 5.5 and 24.3 2θ degrees, indicating the presence of crystalline roflumilast raw material that presents sharp diffraction peaks (Figs. 2 and 3 ). DSC showed a melting endotherm which could be assigned to roflumilast (151.40 ± 0.68°C, ΔH 3.792 ± 0.81 J/g; the melting point for the roflumilast raw material was 159.29°C (Figs. 4 and 5) ).
No changes were observed in the XRPD over a period of 13 weeks for all formulations under the stability conditions of 25°C/60% RH and at 25°C in a sealed desiccator containing sílica gel (data not shown).
The ET formulations presented a characteristic amorphous halo by XRPD and the absence of diffraction peaks in the diffractogram (Fig. 2) . Additionally, DSC demonstrated high glass transition temperatures (T g ) (above 194°C, Table 1) (Fig. 4) . The sample with the highest proportion of HBβCD (ET5R) presented the highest glass transition temperature. The Gordon Taylor equation was used to predict the T g of the spray dried systems (Gordon and Taylor, 1952) , using the HPβCD experimental T g of 232.21 ± 0.86°C and Tg of 25°C for rofumilast (Fig. 5) , resulting in a predicted value of 197.68°C for the 9:1 roflumilast:HPβCD systems. This calculated value compares well with the experimentally determined Tg (Table 1) . HPβCD is an amorphous excipient which has a high glass transition temperature and which has been reported to be able to decrease the degree of crystallinity and inhibit recrystallisation of APIs with which it is co-processed, increasing the physical stability of the system (Amaro et al., 2015b) . The higher the T g , the more stable the glass, that is, the longer it should take to revert back to its crystalline state (Liu et al., 2007) . Hence, ET formulations possess solid state characteristics with promising charcteristics for longer term stability. Fig. 2 . XRPD diffractogram of A) Roflumilast; spray dried formulations: B) MB3; C) ET3; D) ET4; E) ET5; F) ET5N; G) ET5R; H) ET5N after 4 weeks 25°C/desiccant; I) ET5N after 8 weeks 25°C/desiccant; J) ET5N after 4 weeks 25°C/60% humidity; K) ET5N after 8 weeks 25°C/60% humidity; L) ET5N after DVS analysis; M) ET5R after DVS analysis.
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Micromeritic analysis
In order to increase the yield while maintaining suitable characteristics for inhalable formulations, the feed solution concentration was prepared at increasing solute concentration, from 3% (ET3), to 4% (ET4) and 5% w/v (ET5). Particle size volume distributions of spray dried powders were narrow and monomodal in all cases with low span values (between 1.23 and 1.75) and median particle sizes (d 50 ) in the range of 2.57-4.56 µm. Table 1 (2011) and Corrigan et al. (2006) . Therefore, to keep the particle size in the required range, the gas flow rate in the spray dryer used to produce the ET5 powder (473 Nl/h) was increased, with a view to decreasing the particle size, for the ET5N and ET5R formulations (601 Nl/h gas flow). Amaro et al. (2011) and Buchi (2009) have previously presented gas flow rate as a spray drying parameter which may be used to adjust the level of atomization by the spray drying nozzle in order to modify the resulting powder particle size, whereby, when keeping all other process parameters constant, such as concentration and temperature, the gas flow rate can be increased to produce droplets of smaller size. No statistically significant difference in median particle size was found between ET3, ET5N and ET5R (p < 0.05), showing once more how an increase in the atomizing gas (gas flow) can be used to achieve different particle sizes and to conteract the effect of increased solution concentration.
In order to achieve good penetration into the pulmonary regions it is generally accepted that particles should have an aerodynamic diameter between 1 and 5 μm. Such particles deposit maximally in the distal lung and avoid deposition by inertial impaction in the oropharyngeal cavity (Edwards et al., 1998) . Therefore, from a PSD perspective, the spray dried particles appear to present a suitable particle size for inhalation. MMAD assessment, discussed later in the text, will be more a relevant factor to confirm feasibility of pulmonary delivery.
In addition to reducing the particle size when increasing the gas flow, ET5N particles/powder also presented improved specific surface area (higher) and residual solvent (lower) when compared with ET5. Particles with increased surface roughness and surface area lead to higher fine particle fraction (FPF) (Zellnitz et al., 2015) . Previous studies demonstrated that the high SSA of porous particles resulted in increased FPF values, reaching a FPF of more than 50%. At the highest SSA values, fewer areas of contact between particles leads to lower Fig. 4. DSC scans of (A) MB3, (B) ET3, (C) ET4, (D) ET5, (E) ET5N, (F) ET5R, (G) ET5N after 4 weeks 25°C/desiccant, (H) ET5N after 4 weeks 25°C/60% humidity. International Journal of Pharmaceutics 550 (2018) 89-99 cohesion and easier dispersion (Amaro et al., 2011) . High surface roughness can also reduce the adhesion between solid particles, due to the high surface asperities, which may prise the surfaces apart and break the adhesions occurring at the lower asperities (Amaro et al., 2011; Tabor, 1977) . The specific surface area (SSA) of the formulations prepared with 601 Nl/h gas flow rate (ET5N and ET5R) were significantly higher (p < 0.05) than the others prepared with a gas flow of 473 Nl/h ( Table 1 ). The SSA for ET5N and ET5R were not statistically different (p < 0.05), i.e. the proportion of API:excipient had no impact on the SSA. Overall, an increase in concentration of the spray dried solution led to a decrease in SSA, as follows: ET5 < ET4 < ET3. This was to be expected as particle size and SSA are inversely related. The formulation MB3, prepared from a solution in methanol and butyl acetate, showed a high SSA compared with the other formulations (Table 1 ) This effect is due the presence of porosity in the microparticles spray dried from methanol:n-butyl acetate and has been previously demonstrated (Amaro et al., 2011; Healy et al., 2008) .
All formulations presented suitable bulk and tapped densities for pulmonary delivery (Table 1) . Some authors have reported that bulk density less than 0.3 g/cm 3 , as present in this work, is indicative of powders that can achieve a high respirable fraction (Edwards et al., 2005; Healy, et al., 2014; Simon et al., 2016) .
In vitro drug deposition of spray dried formulations
In vitro aerosol deposition profiles using the NGI of spray dried formulations are presented in Fig. 6 . NGI results did not show significant differences between the ET formulations and MB3, probably due to the low points of contact between particles in both cases, due to the presence of pores in the case of MB3, or the wrinkled morphology of the ET formulations. The aerosolization efficiency is characterized by the emitted dose (ED), dispersibility, fine particle fraction (FPF), and mass median aerodynamic diameter (MMAD) (Kho and Hadinoto, 2013) . The FPF was above 50% for all formulations, except for ET5 which has a FPF of 43.88%. The FPF results for our formulations all compare favourably to FPF values of approximately 30% that are typical for lactose carrier-based formulations (Kho and Hadinoto, 2013) . The MMAD values calculated for all formulations were not significantly different (p < 0.05), and were in the range 3.32-4.49 m, which may be considered acceptable for respirable particles (1-5 µm) ( Table 2 ). The GSD values of all spray dried powders were low (≤2.75). A low MMAD value coupled with a low GSD is indicative of a tight size distribution centred on a fine particle size, a potentially beneficial combination for efficient pulmonary delivery (Lewis and Copley, 2010) . Additionaly, all formulations presented high recovered emitted dose contributing to their suitability for pulmonary delivery.
The in vitro deposition profiles and calculated MMAD illustrate the potential for all formulations to exhibit a distribution across the upper and lower airways, where the PDE4 enzyme, which roflumilast inhibits, is found in the smooth muscle of the airways.
Stability studies
DVS was used to evaluate the effect of moisture on the solid-state stability of the selected formulations, ET5N and ET5R. The isotherms of water vapor uptake obtained for the two formulations are shown in Fig. 7 . It was observed that ET5N and ET5R can uptake up to approximately 22.64% and 24.98% of water, respectively, at the end of the sorption cycle at 90% RH and a small hysteresis loop on desorption was observed, with no retention of moisture. ET5N demonstrated slightly higher water uptake than ET5R during the second cycle sorption run. No water was retained in either system post desorption. The high capacity for moisture uptake is probably due to the high proportion of HPβCD in the formulations (Amaro et al., 2015b) . According to the Brunauer, Deming, Deming and Teller (BDDT) classification, the isotherms obtained present the characteristic type IV, which shows a significant uptake at low partial pressures followed by small adsorption at intermediate vapour concentrations and a high uptake again at elevated partial pressures (Brunauer et al., 1940; Sing et al., 1985) . The hysteresis may be due to bulk absorption, since the material is amorphous. The XRPD analysis of the sample ET5R post DVS showed an amorphous halo with no trace of peaks. The XRPD technique is not sensitive enough to detect crystalline roflumilast at this low drug loading and thus it was not possible to determine if roflumilast recrystallized. In contrast, the ET5N formulation presented crystalline peaks of small intensity at 5.15 and 24.3 2θ after the second cycle of analysis in the DVS, indicating the start of roflumilast crystallization (Fig. 2) .
The physical stability of freshly prepared ET5N samples was also assessed under the two stability conditions of 25°C/60% RH and 25°C/ < 10% RH (desiccator). ET5N was selected for stability testing due to its suitable micromeritic and physicochemical characteristics and the fact that it was prepared from the higher feed solution concentration (giving higher yield). The ET5N formulation stored at 25°C/ < 10% RH (desiccator) over a 4 and 8 week period displayed no significant changes in surface morphology (as observed by SEM). The particle morphology changed after 8 weeks storage under 25°C/60% RH. The ET5N particles lost their characteristic morphology and presented less wrinkled particles with either smooth or rough surfaces (Fig. 1) , probably due to absorption of moisture from the humid environment.
Both storage conditions did not affect the amorphous form of the powders by XRPD (Fig. 2) over the 4 and 8-week stability study. The DSC pattern for ET5N after the stability study showed no changes, indicating no crystallization or glass transition temperature depression, under the storage conditions studied ( Fig. 4G and H) . The drug loading did not show any significant difference before and after storage (94% w/w) ( Table 1 ), indicating that the API did not appear to suffer degradation. There was no difference in particle size, specific surface area and bulk and tapped density compared to the starting material at both storage conditions. At 25°C in a constant relative humidity of 60%, an increase in residual solvent content from 5.09% for the starting material to 6.31% was observed due to the high level of humidity and water uptake by the formulation, as observed during DVS analysis.
At all storage conditions, ET5N samples presented similar aerolisation behaviour compared to the freshly spray dried samples, with high emitted dose, FPF < 5 µm value around 50%, MMAD less than or equal to 5 µm and GSD less than 2.6. All samples presented high deposition on stages with lower cut-off points (≤2 μm, stages 3-6). ANOVA with Tukey post hoc test was applied to further confirm comparability of results across the evaluated stability time points. No significant differences were found for the 25°C/60% RH condition. For the 25°C/ < 10% RH (desiccator) stability condition, the only significant difference observed was between the MMAD at week 4 and week 8, however, both were similar to the MMAD determined at the initial time point. (mean ± S.D., n = 3). Fig. 7 . Water vapour sorption and desorption isotherms of A) ET5N, B) ET5R.
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The observed difference was considered to be negligible, as the GSD (geometric standard deviation) was comparable for all time points, this parameter being indicative of the variation within NGI testing performed. Nonetheless, these studies indicate suitable in vitro deposition performance for pulmonary formulations (Fig. 8, Table 3 ).
3.6. Transepithelial permeability using Calu-3
In vitro-in vivo correlation studies have indicated that the Calu-3 is a potentially useful model to predict absorption of drug candidates delivered by oral inhalation (Borchard et al., 2002; Mathias et al., 2002) . The transepithelial permeability characteristics of Calu-3 cell monolayers were evaluated with ET5N and presented an apparent permeability coefficient (P app ) value of 8.73 × 10 −6 ± 4.70 × 10 −7 cm/s. Some inhaled drugs that are used in the treatment of asthma have demonstrated similar permeability behaviour, such as dexamethasone 7.42 × 10 −6 ± 4.94 × 10 −7 cm/s, salbutamol sulfate 1.83 × 10 −6 ± 1.7 × 10 −7 and budesonide 5.33 × 10 −6 ± 0.95 × 10 −6 (Borchard et al., 2002; Mamlouk et al., 2013; Mathias et al., 2002) . Therefore, roflumilast demonstrated potential use in in vivo lung absorption.
Conclusion
Spray drying was a suitable technique to develop roflumilast DPI formulations using HPβCD as excipient/particle matrix, resulting in powders with desirable physicochemical characteristics, physical stability and aerosolization properties, suggesting their potential for pulmonary delivery. Ethanol proved to be a more suitable solvent system than methanol:butyl acetate for spray drying. Stability results were promising, with the solid-state behaviour of the material and aerolisation performance remaining unchanged over 8 weeks for samples stored at 25°C/desiccant and 25°C/60% RH. Studies of longer duration are recommended for future exploration of the developed formulations. In vitro permeability studies indicated and strengthened the potential application of these formulations for pulmonary delivery. In vivo studies in asthma animal model will be performed to enhance the applicability of the roflumilast DPI formulation as a therapeutic agent for pulmonary delivery. Fig. 8 . Aerosol in vitro deposition of spray dried formulations: ET5N) Freshly prepared ET5N; ET5N 4w Des) ET5N after 4 weeks 25°C/desiccant; ET5N 4w 60%) ET5N after 4 weeks 25°C/60% humidity; ET5N 8w Des) ET5N after 8 weeks 25°C/desiccant; ET5N 8w 60%) ET5N after 8 weeks 25°C/ 60% humidity; MA -mouth adapter; IP -induction port.
Table 3
The emission, the fine particle fraction, mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of ET5N on stability at 25°C/60% RH and 25°C/desiccant analysed over an 8 week period. (mean ± S.D., n = 3).
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